Skip to content
Screener

Shares (Diluted) at other companies

HRO
HarrowHROW
37.4M-3.9%
XER
Xeris Biopharma Holdings, Inc.XERS
172.8M+8.4%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
21.9M+7.9%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
61.3M+8.9%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
101.9M+3.5%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
19.7M+8.3%

Other financials

Income statement

See full
Revenue$24.3M+40.4%
Gross profit$14.7M+49.4%
Operating income$2.4M+614%
Net income$1.6M+199%
EPS (diluted)$0.05+183%

Balance sheet

See full
Cash & equivalents$19.7M+12.9%
Total debt$31.3M+3.7%
Total equity$30.6M+25.2%
Total assets$97.7M+16.3%

Cash flow

See full
Operating cash flow$7.4M+254%
CapEx$75.0K
Free cash flow$7.3M+251%

Valuation

See full
Market cap$1.26B+209%
Enterprise value$1.28B+208%
P/S14.6×+7.5×

Profitability

See full
Gross margin54.8%-3.7pp
Operating margin-15.1%
Net margin-9.5%-2.7pp
FCF margin17.1%

Returns & leverage

See full
Return on equity-34.2%+0.9pp
Debt / equity-0.2×
Current ratio1.2×-0.8×

Where this comes from

Reported directly by Eton Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 4:17 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001437749-26-017064
Line itemFor the three months ended / March 31, 2026For the three months ended / March 31, 2025
Interest and other expense, net(840)(1,028)
Income (loss) before income tax expense1,574(1,498)
Income tax expense2074
Net income (loss)$1,554$(1,572)
Net income (loss) per share, basic$0.06$(0.06)
Weighted average number of common shares outstanding, basic27,28526,886
Net income (loss) per share, diluted$0.05$(0.06)
Weighted average number of common shares outstanding, diluted31,54726,886

Document

FAQ

What is Eton Pharmaceuticals, Inc.'s shares (diluted)?
Eton Pharmaceuticals, Inc. (ETON) reported shares (diluted) of 31.5M in Q1 2026.
How has Eton Pharmaceuticals, Inc.'s shares (diluted) changed year-over-year?
Eton Pharmaceuticals, Inc.'s shares (diluted) increased by 17.3% year-over-year, from 26.9M to 31.5M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about Eton Pharmaceuticals, Inc.'s shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude